The U.S. Food and Drug Administration (FDA) granted abelacimab a fast track designation in 2022, highlighting its potential to transform stroke prevention in atrial fibrillation patients and combat cancer-associated thrombosis—two high-risk conditions with significant unmet medical needs.
Anthos CEO: Novartis is “Best Positioned” to Lead
Anthos CEO Bill Meury expressed confidence in Novartis’ ability to push abelacimab to the finish line. “Novartis is well positioned to advance abelacimab’s clinical development and bring this innovative product to healthcare providers and patients,” he said.
Novartis’ David Soergel, global head of cardiovascular, renal, and metabolism development, echoed that sentiment. “We are proud that this medicine originated at Novartis and have been impressed with the Anthos Therapeutics team’s expertise and dedication,” he said.
Closing Conditions & Legal Advisors
The deal remains subject to standard closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to finalize by June.
